PAncreatic Disease Cohort of TOuLouse

Pancreatic Diseases Clinical Trial

— PACTOL  

Official title:

PAncreatic Disease Cohort of TOuLouse

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05824403
• Other study ID #: RC31/22/0530
• Status: Recruiting
• Start date: November 28, 2023
• Est. completion date: December 2027

Study information

• Verified date: November 2023
• Source: University Hospital, Toulouse
• Contact: Barbara BOURNET, MD
• Phone: 0561323235
• Email: bournet.b[@]chu-toulouse.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is a prospective cohort dedicated to pancreatic diseases excluding cancer. The aim is to develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies. During this study the investigators collect data and biological samples to support research project.

Description:

This collection focuses on pathology of the pancreas requiring specific investigations or management for diagnosis or treatment. Pancreatic pathologies can be classified as malignant, potentially malignant or benign tumors. These can be solid or cystic. There is an inflammatory attack on the pancreas, generating acute pancreatitis in the acute period, if the inflammatory manifestations persist, chronic pancreatitis will develop. Some lesions may be at risk of malignancy during their evolution, it is therefore necessary to improve the performance of monitoring and diagnostic tools in order to adapt the management of patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: December 2027
• Est. primary completion date: December 2027
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with inflammatory or cystic exocrine pancreatic pathology
• Patient able to read and understand the information leaflet
• Patients who have agreed to participate in the study and have signed the free and informed consent
• Patients affiliated to a social security system (including AME)

Exclusion Criteria:

• Patient with pancreatic cancer pathology
• Patients with active cancer, whatever the origin
• Pregnant or breastfeeding patients
• Patients under legal protection, guardianship or trusteeship

Related Conditions & MeSH terms

• Pancreatic Diseases

Locations

Country	Name	City	State
France	Rangueil hospital	Toulouse

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Toulouse

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnostic tools	To develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies	3 years after the first inclusion
Secondary	New targets	To identify new screening targets	3 years after the first inclusion
Secondary	Improvement of management	To improve the management of cystic lesions or Chronic pancreatitis on the decision of therapeutic management	3 years after the first inclusion
Secondary	Microbiota	Study of the microbiota of pancreatic diseases	3 years after the first inclusion
Secondary	Clinical data access	To make available to the scientific community quality material with associated clinical data also of quality	3 years after the first inclusion